Aegis Reiterates Hold Rating for Inovio Pharmaceuticals (INO)
Shares of Inovio Pharmaceuticals (NYSE:INO) traded up 9.44% during mid-day trading on Monday, hitting $10.78. 3,413,431 shares of the company’s stock traded hands. Inovio Pharmaceuticals has a 52 week low of $2.44 and a 52 week high of $15.80. The stock’s 50-day moving average is $9.17 and its 200-day moving average is $10.59. The company’s market cap is $648.5 million.
Inovio Pharmaceuticals (NYSE:INO) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.04) by $0.01. The company had revenue of $2.40 million for the quarter, compared to the consensus estimate of $1.41 million. Analysts expect that Inovio Pharmaceuticals will post $-0.69 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Stifel Nicolaus initiated coverage on shares of Inovio Pharmaceuticals in a research note on Wednesday, May 7th. They set a “buy” rating and a $16.00 price target on the stock. Separately, analysts at Zacks downgraded shares of Inovio Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Friday, April 18th. They now have a $12.80 price target on the stock. Finally, analysts at Zacks upgraded shares of Inovio Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Thursday, March 20th. They now have a $16.00 price target on the stock. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Inovio Pharmaceuticals presently has an average rating of “Buy” and an average price target of $18.96.
Inovio Pharmaceuticals, Inc is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.